重度哮喘的生物标志物研究进展  

Advances in biomarker research for severe asthma

作　　者：刘辉[1,2] 孔晓梅 Liu Hui;Kong Xiao-mei(Academy of Medical Sciences,Shanxi Medical University,Taiyuan,Shanxi 030001,China;Department of Respiratory Critical Care Medicine,Shanxi Medical University Affiliated First Hospital,Taiyuan,Shanxi 030001,China)

机构地区：[1]山西医科大学医学科学院,山西太原030001 [2]山西医科大学第一医院呼吸与危重症医学科,山西太原030001

出　　处：《中国现代医学杂志》2025年第5期53-59,共7页China Journal of Modern Medicine

基　　金：国家自然科学基金(No:82370024)。

摘　　要：重度哮喘是复杂异质性慢性炎症疾病。近年来,伴随着对重度哮喘发病机制认识的不断深入,其生物标志物的研究取得了显著性进展,其诊断和治疗策略也得到了显著改善。每一种生物标志物都以其独特的方式为重度哮喘的精准医疗提供重要信息。结合国内外最新的研究进展,该文综述了现有及未来可能改善重度哮喘诊疗的新兴组学生物标志物,这些标志物能快速揭示疾病的病理生理过程,进而为精准诊断和个体化治疗提供可靠依据。Severe asthma,characterized as a complex and heterogeneous chronic inflammatory disease,has witnessed significant advancements in biomarker research alongside a deepening understanding of its pathogenesis in recent years.These advancements have markedly improved diagnostic and therapeutic strategies for this condition.Each biomarker contributes uniquely to precision medicine in severe asthma by providing critical insights into its molecular underpinnings.This review synthesizes the latest global research progress on existing and emerging omics-based biomarkers that hold promise for refining the management of severe asthma.These biomarkers rapidly elucidate disease-specific pathophysiological pathways,thereby offering robust evidence to guide precision diagnosis and tailored therapeutic approaches.Furthermore,we highlight future directions in biomarker discovery,emphasizing their potential to overcome current limitations in phenotyping and therapeutic resistance.

关 键 词：重度哮喘 生物标志物 未来方向 

分 类 号：R562.25[医药卫生—呼吸系统]